Carolien H M van Deurzen
Overview
Explore the profile of Carolien H M van Deurzen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
2736
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baez-Navarro X, Van Bockstal M, van der Made A, van Deurzen C
Arch Pathol Lab Med
. 2024 Oct;
PMID: 39471829
Context.—: Breast cancers (BCs) with low levels of human epidermal growth factor receptor 2 (HER2) expression (HER2-low) have become a targetable subset because of novel antibody-drug conjugates. HER2 immunohistochemistry (IHC)...
2.
Van Bockstal M, Wesseling J, Lips E, Smidt M, Galant C, van Deurzen C
Breast Cancer Res
. 2024 Aug;
26(1):125.
PMID: 39192322
In many countries, hormone receptor status assessment of ductal carcinoma in situ (DCIS) is routinely performed, as hormone receptor-positive DCIS patients are eligible for adjuvant anti-hormonal treatment, aiming to reduce...
3.
Leon-Ferre R, Jonas S, Salgado R, Loi S, de Jong V, Carter J, et al.
JAMA
. 2024 Apr;
331(13):1135-1144.
PMID: 38563834
Importance: The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with...
4.
Baez-Navarro X, van den Ende N, Nguyen A, Sinke R, Westenend P, van Brakel J, et al.
Breast Cancer Res
. 2024 Mar;
26(1):41.
PMID: 38468323
Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy has demonstrated promising results in TNBC, due to...
5.
Baez-Navarro X, Van Bockstal M, Jager A, van Deurzen C
Pathology
. 2024 Feb;
56(3):334-342.
PMID: 38341307
About half of breast cancers (BC) without amplification of the human epidermal growth factor receptor 2 (HER2) have a low HER2 protein expression level (HER2-low). The clinical impact of HER2-low...
6.
Qu S, Timmermans A, Heemskerk-Gerritsen B, Trapman-Jansen A, Broeren-Foekens R, Prager-van der Smissen W, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201455
The ferritin-heavy chain (FTH1) is the catalytic subunit of the ferroxidase ferritin, which prevents oxidative DNA damage via intracellular iron storage. FTH1 was shown to be a prognostic marker for...
7.
Oztekin S, Hooning M, van Deurzen C, Dietvorst A, Drooger J, Kitzen J, et al.
Cancer
. 2023 Nov;
130(6):927-935.
PMID: 37985357
Background: Despite histological and molecular differences between invasive lobular carcinoma (ILC) and invasive carcinoma of no special type, according to national treatment guidelines no distinction is made regarding the use...
8.
Baez-Navarro X, Van Bockstal M, Andrinopoulou E, van Deurzen C
Mod Pathol
. 2023 Nov;
36(12):100356.
PMID: 37951019
No abstract available.
9.
Wang Y, Broeks A, Giardiello D, Hauptmann M, Jozwiak K, Koop E, et al.
Eur J Cancer
. 2023 Nov;
195:113401.
PMID: 37925965
Background: The validity of the PREDICT breast cancer prognostic model is unclear for young patients without adjuvant systemic treatment. This study aimed to validate PREDICT and assess its clinical utility...
10.
Ladan M, Meijer T, Verkaik N, de Monye C, Koppert L, Oomen-de Hoop E, et al.
NPJ Breast Cancer
. 2023 Sep;
9(1):80.
PMID: 37777518
We developed a functional ex vivo anthracycline-based sensitivity test. Surgical resection material of primary breast cancer (BC) was used to determine criteria for the ex vivo sensitivity assay based on...